CN1032443A - 用于制备ace抑制剂的次膦酸和中间体的制备方法 - Google Patents
用于制备ace抑制剂的次膦酸和中间体的制备方法 Download PDFInfo
- Publication number
- CN1032443A CN1032443A CN88109034A CN88109034A CN1032443A CN 1032443 A CN1032443 A CN 1032443A CN 88109034 A CN88109034 A CN 88109034A CN 88109034 A CN88109034 A CN 88109034A CN 1032443 A CN1032443 A CN 1032443A
- Authority
- CN
- China
- Prior art keywords
- formula
- alkyl group
- low alkyl
- salt
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 phospho Chemical class 0.000 title claims abstract description 37
- 239000002253 acid Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000000543 intermediate Substances 0.000 title description 5
- 239000005541 ACE inhibitor Substances 0.000 title description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 150000002148 esters Chemical class 0.000 claims abstract description 12
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 150000007530 organic bases Chemical class 0.000 claims abstract description 8
- 238000007327 hydrogenolysis reaction Methods 0.000 claims abstract description 6
- 238000001953 recrystallisation Methods 0.000 claims abstract description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 33
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical group ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 230000018199 S phase Effects 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical group OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 claims description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012964 benzotriazole Substances 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 238000003763 carbonization Methods 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract description 2
- 229940125532 enzyme inhibitor Drugs 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 18
- 238000005406 washing Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 9
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 9
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000001291 vacuum drying Methods 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 3
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 3
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 3
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XDWMFKDCNAOMFT-UHFFFAOYSA-N acetyloxy(4-phenylbutyl)phosphinic acid Chemical compound CC(=O)OP(O)(=O)CCCCC1=CC=CC=C1 XDWMFKDCNAOMFT-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 1
- IQDIERHFZVCNRZ-YUYPDVIUSA-N Imperialine Chemical compound C([C@@H]1C(=O)C[C@H]2[C@@H]3CC[C@@H]4[C@]5(C)O)[C@@H](O)CC[C@]1(C)[C@H]2C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 IQDIERHFZVCNRZ-YUYPDVIUSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000425037 Toona sinensis Species 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3264—Esters with hydroxyalkyl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
一种制备次膦酸化合物及其盐和立体异构体的
方法。这类化合物用于制备某些血管紧张素转化酶
抑制剂,这类化合物的结构式为(I)。
该方法包括下列步骤:在有机碱存在下,式II结
构的次膦酸酯与式III结构的卤代酯反应,形成式IV结
构的次膦酸酯,将上述酯氢解,形式式I结构次膦酸
非对映异构体混合物,经重结晶回收主要的外消旋混
合物,然后用拆分剂,最好是L-辛可尼定,拆分该混
合物,得到相应的经过拆分的盐,将后者酸化得到相
应的酸。另外,还提供了前述酸式和盐式新中间体。
Description
一种制备式Ⅰ所示次膦酸化合物及其盐和立体异构体的方法,该类化合物用于制备某些血管紧张素转化酶抑制剂,如授予(Petrillo)的美国专利4,337,201号所述。另外还包括下文所述新的中间体。式Ⅰ为:
式中R1是低级烷基,芳基,芳烷基,环烷基或环烷基烷基;
R2是氢,低级烷基或芳烷基;
X是氢,低级烷基或苯基;
n是0或1。
按照本发明,提供了制备结构式ⅠA所示化合物及其盐和所有立体异构体的方法,式ⅠA为:
式中R1是低级烷基,芳基,芳烷基,环烷基或环烷基烷基;
R2是氢,低级烷基或芳烷基;
X是氢,低级烷基或苯基;
n是0或1,
该方法包括下列步骤:在有机碱存在下,式Ⅱ结构次膦酸酯与式Ⅲ结构囟代酯反应,生成式Ⅳ结构次膦酸酯,式Ⅱ为:
式中R3是易氢解基团,具体是苄基或取代苄基,例如,
(式中R′ 3是在邻-,间-或对位取代的烷基,烷氧基,烷酰基,苯基或二烷基氨基),式Ⅲ为:
式中Hal是Cl或Br,X和y定义如前。式Ⅳ为:
在氢化催化剂存在下(如:钯-炭或其他常用的钯催化剂)用氢处理,将式Ⅳ次膦酸酯氢解,得到一对式ⅠA′结构化合物的外消旋混合物(或者是两个非对映异构体的混合物,ⅠA为:
即,下列异构体的混合物:
B-异构体(ⅠA)
A-异构体(ⅠB)
C-异构体(ⅠC)
D-异构体(ⅠD)
通过用乙酸异丁基酯或甲基异丁基酮重结晶,分出ⅠA和ⅠB的外消旋混合物,ⅠA为:
通过用析分剂,例如,L-辛可尼定或其他惯用的析分剂(旋光活性胺),拆分该外消旋混合物,可以得到式Ⅴ结构的经过拆分的盐:
Ⅴ·拆分剂
可以用强酸或酸式盐(例如,硫酸氢钾,盐酸,或硫酸)处理经过拆分的盐Ⅱ,如:
由此得到酸式ⅠA。
次膦酸酯Ⅲ与囟代酯Ⅲ的反应可以在有机溶剂中,并在有机碱的存在下进行,有机碱包括:三乙胺,吡啶,三丙胺,二氮杂双环十一碳烯(DBU),或任何其他普通的有机碱,但最好是三乙胺;有机溶剂包括:甲苯,氯仿,乙腈,二氯甲烷,乙醚,四氢呋喃或二噁烷,但最好是甲苯;还可以任意地加入催化剂,例如,硫酸四丁铵和碘化钠。
所使用的次膦酸酯Ⅱ与囟代酯Ⅲ的摩尔比应该在约0.1∶1至约1∶1之间,但最好是约0.2∶1至约0.3∶1,Ⅱ与Ⅲ的反应温度应在约50至约130℃之间,反应时间应在约2至约12小时。
采用下述方法拆分外消旋混合物(ⅠA-ⅠB),(由酯Ⅳ经氢解,继之经梯度结晶制得),即:在惰性有机溶剂中用拆分剂处理ⅠA和ⅠB的外消旋混合物,所说拆分剂包括L-辛可尼定或其他旋光活性胺,但最好是L-辛可尼定,所说溶剂包括乙酸乙酯,乙醇,或四氢呋喃,但最好是乙酸乙酯。进行上述反应的温度为约25至约80℃之间,反应时间为约2至约12小时,所用拆分剂与ⅠA和ⅠB外消旋混合物的摩尔比为约2∶1至约0.2∶1,但最好是约1∶1至约0.5∶1。
包括其所有立体异构体(例如,ⅣA,如,ⅣA′,)在内的中间体Ⅴ,和包括其所有立体异构体(例如,ⅠA,如:ⅠA′)在内的中间体ⅠA′,以及中间体Ⅴ·拆分剂(例如,ⅤA·辛可尼定,如:ⅤA′·辛可尼定)均是新化合物,它们的结构式如下:
用作起始原料的Ⅱ式次膦酯是已知化合物:
该化合物可按美国专利4,602,092号所述方法制备:苄基酯可按美国专利4,602,092号中实施例1所述方法制备。
另外,通过将式ⅣA结构次膦酸化合物酯化,也可制得次膦酸酯Ⅱ,式ⅣA为:
具体方法为:(a)用醇(如:甲醇或乙醇或苄醇,但最好是苄醇)处理式11A次膦酸化合物,反应温度为约25至约130℃,反应时间为约2至约10小时,或者(b)在碱存在下,于有机溶剂中,用氯甲酸烷基酯处理式11A次膦酸化合物,所说氯甲酸烷基酯包括:氯甲酸乙酯或甲酯,或氯甲酸芳烷基酯,如:氯甲酸苄基酯,但最好是氯甲酸苄基酯,所说碱包括:三乙胺,吡啶或N,N-二乙胺,所说有机溶剂包括:甲苯,四氢呋喃或二噁烷,上述反应(b)的反应温度为约-30℃至约30℃,反应时间为约1至约4小时。
就进行上述反应(a)或(b)而言,所使用的式11A次膦酸化合物与醇或氯甲酸酯化合物之摩尔比应为约0.2∶1至约1∶1,最好是约0.5∶1至1∶1。
贯穿于本说明书中所采用的术语“芳基”,无论其本身还是作为大基团的部分,意指苯基或萘基,或者是由下述基团取代的苯基或萘基:囟素,烷基,烷氧基,烷硫基,羟基,烷酰基,硝基,氨基,二烷基氨基,或三氟甲基。优选者是苯基或单取代苯基,最佳者是苯基。
贯穿于本说明书中所采用的术语“烷基”或“低级烷基”,无论其本身还是作为大基团的部分,意指含有1至10个碳原子的基团,并且该基团可以含有1或2个囟素(Cl,I,Br或CF3),低级烷氧基,芳基或环烷基取代基。优选者是含1至4个碳原子的烷基。
贯穿于本说明书中所采用的术语“环烷基”,无论其本身还是作为大基团的部分,意指含有3至7个碳原子的基团,例如,环丙基,环丁基,环戊基,环己基或环庚基。
贯穿于本说明书中所采用的术语“烷氧基”或“烷硫基”,无论其本身还是作为大基团的部分,意指含1至8个碳原子的基团,优选者是含1至3个碳原子的烷氧基或烷硫基。
贯穿于本说明书中所采用的术语“芳烷基”或“环烷基烷基,无论其本身还是作为大基团的部分,意指定义如前的,含有“芳基”或“环烷基”取代基的“烷基”。
如美国专利4,337,201号所公开的,式ⅠA次膦酸化合物可用于制备ACE抑制剂,例如,在偶合剂和致活剂以及碱的存在下,式ⅠA次膦酸,如ⅠA′,与式Ⅷ结构化合物或其游离氨基酸反应,并从该反应混合物中回收所期产物,由此制得式Ⅶ化合物,式Ⅶ为:
所说偶合剂包括:N,N′-二环己基碳化二亚胺,混合酐试剂,如:新戊酰氯,羰基二咪唑或巯基苯并三唑或其他常用的偶合剂,所说活化剂包括:N-羟基琥珀酰胺或羟基苯并三唑,所说的碱包括:二异丙基乙胺或三乙胺。
在进行上述反应时,所采用的ⅠA′与Ⅷ的摩尔比为约0.5∶1至约2∶1,反应温度为约-20至约30℃,反应时间为约2至约12小时。
在实施本发明时,可用作起始原料的次膦酸酯包括,但不限于下列化合物:
适用于本文的囟代酯Ⅲ包括但不限于下列化合物:
下列实施例代表本发明的优选实施例。除另外说明外,所有温度均以摄氏温度表示。
实施例1
[[2-甲基-1-(1-氧丙氧基)丙氧基](4-苯基丁基)氧膦基]乙酸(异构体B)辛可尼定盐(1∶1)
A.[羟基(4-苯基丁基)氧膦基]-乙酸苄基酯
将三乙胺(3.2ml,0.022mole)加到4-苯基丁基次膦酸(2.0g,0.01mole)的氯仿?0ml)溶液中,将该混合物在冰浴中冷却至0℃,将氯代三甲基硅烷(2.8ml,0.022mole)滴加到上述溶液中,继之加入溴乙酸苄基酯(1.6ml,0.011mole)。去掉冰浴,并将该混合物在室温下搅拌5小时,然后倒入10%盐酸(30ml)和碎冰(20g)中。该混合物经在分液漏斗中振荡后,分出氯仿层,并用二氯甲烷(2×50ml)提取水层,合并提取液,并用盐水洗涤,用无水硫酸钠干燥,旋转蒸发除去溶剂。将所得粗制粘油(3.5g)溶于30ml醚中,滴加己烷,得到一混浊溶液,将该混合物在室温下放置过夜使之完全结晶,在冰柜中冷却2小时,过滤,依次用己烷(50ml),乙醚(50ml),己烷(50ml),乙醚(50ml)将固体充房洗涤,将该固体真空干燥,得到2.48g(71%)题目化合物,m.p.68-70℃,TLC(硅胶)CH2Cl2∶MeOH∶HOAc(20∶1∶1)在R0.25处显示单斑点。
元素分析C19H23O4P:
计算值:C,65.88;H,6.69;P.8.94;
实验值:C,65.88;H,6.77;P.8.5。
B.[[2-甲基-1-(1-氧丙氧基)丙氧氧](4-苯基丁基)氧膦基]乙酸苄基酯。
将50g(0.14mole)前文A中制得的酯化合物溶于300ml无水CHCl3中,并用28.6g(0.28mole)Et3N,35.6g(0.21mole)丙酸1-氯异丁基酯,12.0g(0.035mole)(n-Bu)4NHSO4,5.3g(0.035mole)NaI处理该溶液。
搅拌上述混合物,并加热使之温和回流20小时,然后冷却,真空蒸除溶剂。将油状残留物溶于150ml乙醚中,并用150ml H2O洗涤。用150ml乙醚(4X)提取水洗液。合并醚溶液,依次用5%NaHCO3(3×150ml),10% NaHSO4和盐水洗涤。经干燥(MgSO4)后,真空蒸掉乙醚,得到57.0G(83%)粗制油状产物。
元素分析C26H35O6P:
计算值:C,65.80;H,7.43,
实验值:C,64.56;H,7.40
C.[[2-甲基-1-(1-氧丙氧基)丙氧基](4-苯基丁基)氧膦基]乙酸(外消旋混合物对或非对映异构体混合物)
将前文B中制得的化合物57.0g(0.12mole)溶于300ml乙酸乙酯中,用3.0g10%pd/c处理之,并在Parr装置中(45psi)氢化4小时。该混合物通过Hyflo过滤,并用5%NaHCO3(3×150ml)提取该溶液。用醚洗涤该水提取液,冷至5℃,用36ml HOAc处理。用乙酸乙酯(2×200ml)提取该产物,干燥(MgSO4),真空蒸发溶剂。将残留物溶于300ml甲苯中,真空蒸除溶剂,除去最后痕量的HOAc。室温下放置,该油状残留物变为半固体,得量为39.8g(按A酯计算,收率为72%)。
元素分析:C19H29O6P:
计算值:C,59.36;H,7.60,
实验值:C,59.30;H,7.62。
D.[[2-甲基-1-(1-氧丙氧基)丙氧基](4-苯基丁基)氧膦基]乙酸(A/B异构体,外消旋混合物)。
将前文C中制得的化合物混合物10.0g(0.026mole)悬浮于50ml异丙醚中,将该悬浮液猛烈地搅拌15分钟,然后于5℃放置20小时。
滤出无色产物,用少量冷异丙醚洗涤,得到5.0gA/B异构体,m.p.87-89°。真空蒸发滤液,并留作分离C/D异构体。
将上述物质溶于110ml热异丙醚中,通过热玻璃漏斗(玻璃棉)过滤,冷却溶液,得到4.6g(92%)所期产物,m.mp.90-92°。
E.[[2-甲基-1-(1-氧丙氧基)丙氧基](4-苯基丁基)氧膦基]乙酸(拆分:异构体B)辛可尼定盐(1∶1)
猛烈搅拌980g(3.33mol)L-辛可尼定于6升乙酸乙酯的悬浮液,并将温度维持在45℃,在此条件下,逐步加入1275.5g(3.33mol)前文D中A/B异构体混合物,然后再连续搅拌2.5小时,同时将形成的盐悬浮液渐热到70℃,此时形成完全溶液。经过滤(Hyflo)除去少量的不溶性物质,并将该溶液接种,冷却。过滤分离结晶产物,用1200ml乙酸乙酯/异丙醚(1∶1)洗涤,真空干燥,得到1897.2g富B-异构体的辛可尼定盐,m.p.106-109℃,[α]D=-59.3°(C=1,甲醇),[α]365=-237.6°(c=1,甲醇)。将该物质与136.8g以类似方法制得的物质(由0.412mol前文D中A/B异构体制得)混合,将混合后的所有物质(2014g)用10.18升煮沸乙酸乙酯重结晶,过滤,用1500ml与前面所使用的同一溶剂混合物洗涤,真空干燥,得到1162g(92%)题目B-异构体辛可尼定盐,m.p.120-122℃(分解),[α]D=-45.2°(C=1,甲醇),[α]365=-185.5°(C=1,甲醇)。
将样品(10g)再用乙腈重结晶两次,用乙酸乙酯重结晶三次,得到盐,m.p.125-126℃(分解),[α]D=-42.2°,[α]360=-178.8°,Rf0.38)SiO2-CHCl3/MeoH,1∶9)。
元素分析C19H29OP·C19H22N2O:
计算值:C,67.23;H,7.57;N,4.13;
实验值:C,67.17;H,7.62;N,4.14。
实施例2
[[2-甲基-1-(1-氧丙氧基)丙氧基](4-苯基丁基)氧膦基]乙酸A.[羟基(4-苯基丁基)氧膦基]乙酸苄基酯
将[羟基-(4-苯基丁基)氧膦基]乙酸(按美国专利4,602,092实施例23所述方法制得)(422.5g,1.65mole)溶于四氢呋喃(4700ml,经矾土纯化)中,充分搅拌,并将温度维持在-5℃至-10℃,然后逐步加入三乙胺(290ml,2.08mole)。继之滴加氯甲酸苄基酯(275ml,1.93mole)的纯化四氢呋喃(1320ml)溶液。撤去冷浴后,继续搅拌3小时。此后,将该反应混合物过滤。用乙酸乙酯(2×1000ml)洗涤固体。合并滤液,真空浓缩。将所得残留物溶于乙酸乙酯(4000ml)中,依次用水(2×1000ml)2.5%盐酸(2×600ml),盐水(2×1000ml)洗涤。有机层用硫酸镁干燥,过滤,浓缩。用乙醚/己烷(1∶1)(2×500ml)研究残残留物,过滤收集产物,在玻璃滤板上用乙醚/己烷(1∶1)洗涤固体,然后于30℃真空干燥过夜,得到509g无色结晶产物,m.p.68-70℃。
元素分析C19H23O4P:
计算值:C,65.89;H,6.69;P,8.94;
实验值:C,65.80;H,6.80;P,9.10。
B.丙酸1-氯异丁基酯
将氯化锌(7.4g)加到猛列搅拌,冰冷却的丙酰氯(140g,14.8mole)·氯仿(经3A分子筛干燥)(3000ml)溶液中,继之滴加异丁醛(1132g,14.8mole)(放热),滴加速度应使反应温度保持在25℃(3小时)。
在不间断冰浴冷却的条件下,将该反应混合物再搅拌30分钟。然后撤去冰浴,并连续搅拌1小时。然后依次用水(3×1500ml)洗涤反应混合物,经硫酸镁干燥后,将有机层过滤,真空浓缩。残留油状经蒸馏得到2269g无色液体,b.p.46-48℃(4.5mm)。
C.[[2-甲基-1-(1-氧丙氧基)丙氧基)(4-苯基丁基)氧膦基)乙酸。
将实施例1第E部所制得的盐(406.8g,0.6mole)悬浮于乙酸乙酯(4800ml)和水(2700ml)的混合物中,搅拌下滴加硫酸氢钾(180g)水(700ml)溶液(pH=2.3)。分离有机层,用盐水(1×1000ml)洗涤,用无水硫酸镁干燥(2小时)。合并后的水层用乙酸乙酯(3×1500ml)再提取,并按上述操作处理提取液。将合并后的乙酸乙酯洗液过滤,真空浓缩。残留物与甲苯(3×1300ml)共沸,然后真空干燥3天,得到230.4g题目游离酸。
实施例3
[1(±)-4-环己基-1-[[[2-甲基-1-(1-氧丙氧基)丙氧基](4-苯基丁基)氧膦基]乙酰基]-L-脯氨酸单钠盐(异构体B)
在冰/丙酮浴欣淙从上铝形镏首槌傻慕椿旌衔?实施例2酸(经室温下真空干燥72小时)(230.4g,0.6mole),羟基苯并三唑水合物(经80℃真空干燥24小时)(101.1g,0.66moles),Burdick&Jackson二氯甲烷(经分子筛干燥)(6升)。然后用N,N-二环己基碳化二亚胺(DCC)(136g,0.66mole)处理上述混合物。将该混合物温热至室温,搅拌3小时。然后在冰/丙酮中冷却该混合物,并用反-4-环己基-1-脯氨酸盐酸盐(154.2g,0.66mole)处理之,继之加入二异丙基乙胺(170.7g,1.32mole)。将该反应混合物在室温搅拌18小时。然后将该混合物冷却,用水(1升)处理,真空浓缩除去二氯甲烷。用乙醚(3600ml)和水(3600ml)稀释残余物,过滤。用10%的盐酸将滤液调至pH-1.8。分离醚层,用乙酸乙酯(3×2升)洗涤水层。合并有机层,依次用5%KHSO4(3×1升),水(3×1升),盐水(1升)洗涤,用硫酸镁干燥,真空浓缩,得到398.9g粗产品。
将该粗产品溶于丙酮(4393ml)中,用2-乙基己酸钠(117.3g)的丙酮(1468ml)溶液处理,然后在室温搅拌过夜。过滤收集所得沉淀,用丙酮(3×400ml)和己烷(1升)洗涤,然后真空干燥,得到产品277g,m.p.195-196℃[α]D=-5.1(meOH,C=2)HI=99.8%,未发现异构体“A”。
合并分四批偶合反应而得到的产物,由此得到所有题目产物,并通过采用实施例2酸使所形成的钠盐沉出(四步分别为38.4g,115g,230g,230g)。合并四步偶合反应所得固体,并将其置于4000ml异丙醇(预热至40℃)中再浆化,然后在40℃猛烈搅拌15分钟。将该浆状物冷至室温,过滤,该过滤过程非常缓慢,几乎需要6小时。该滤饼再先后用异丙醇和乙醚洗涤。该固体于室温下真空干燥,得到710g题目产物。m.p.195-196℃。[α]D=-5.1°(MeOH,C=2)HI=99.9,未见异构体“A”。
实施例4
[羟基(4-苯基丁基)氧膦基]乙酸苄基酯
在18.75ml甲苯中混合[羟基-(4-苯基丁基)氧膦基]乙酸(5g),苄醇(2.21g),催化量的对甲苯磺酸(44mg)。将该混合物加热至回流(+108℃),维持回流,直到HPLC分析表明不再消耗起始酸为止(约7小时)。将在该反应过程中产生的水滞留于回流系统的支路。反应完全后,如起始酸稍有变色(棕黄色),可于80℃至90℃在该混合物中加入DARCOG-60(2.2g,按起始酸计算,4.5wt%)。在结晶前,从混合物中滤除DA-RCO。
将澄清的反应溶液冷却至60℃,加入戊烷(19.53ml),使其结晶。将该反应物冷至结晶温度(25℃至29℃),并在该温度下至少保温90分钟。将所得浆状物冷至0℃至5℃,过滤前在该温度下至少保温2小时。用3×0.5滤饼体积的己烷/甲苯(2∶1V/V)洗涤滤饼,真空下于40℃干燥该结晶产物,直到残留溶剂低于0.5wt%。
这一方法的收率约为88M%。
如果需要将题目化合物进行重结晶,在55℃至60℃,将其溶于10ml甲基异丁基酮中。将该溶液净化过滤,然后冷却至25℃至30℃,以使题目酸化合物结晶。然后将该浆状物冷却至0℃至5℃过滤。用2×0.5滤饼体积的冷(0℃至5℃)甲基·异丁基酮洗涤滤饼。真空下,于35℃干燥产物,直到残留溶剂完全消失为止。
实施例5
[[2-甲基-1-(1-氧丙氧基)丙氧基](4-苯基丁基)氧膦基]乙酸。
在12ml甲苯中,将4g实施例4化合物与2.34g三乙胺和3.80g实施例2B部分的酯一起回流(112℃)近8小时,形成题目酸的苄基酯。冷却后,滤掉三乙胺盐酸盐,用氢和0.2g 5%(50%水湿剂)钯-炭处理该富甲苯滤液,借以使该苄基酯去保护。
滤出催化剂后,将产品萃取入16ml 5%碳酸氢钠溶液中。用近1.32ml浓盐酸将该水溶液酸化至pH3.0,然后将该产物萃取入16ml乙酸异丁酯(IBA)中。通过浓缩和冷却IBA,分离湿结晶固体状题目酸(IA/IB)异构体对)。
该湿滤饼在甲基·异丁基酮(MIBK)中重结晶,得到含0.1%或更少IC/ID异构体对的产物(1.3g)。
Claims (12)
1、制甘絀A化合物及其盐和所有立体异构体的方法,
式中R1是低级烷基,芳基,芳烷基,7环烷基或环烷基烷基;
R2是氢,低级烷基或芳烷基;
X是氢,低级烷基,或苯基;
Y是氢,低级烷基,苯基或烷氧基,或者X和Y一起为-(CH2)2-,-(CH2)3,-CH=CH-或 和
n是0或1,
该化合物是以其盐的形式Ⅴ制得的;
,
Ⅴ·拆分剂
式中R1,R2,n,X和y定义如前,该方法包括:在有机碱存在下,式Ⅱ为次膦酸酯与式Ⅲ囟代酯反应,形成式Ⅳ次膦酸酯,式Ⅱ为:
式中R3是易氢解基团,具体为苄基, 式中R′是烷基,烷氧基,烷酰基,苯基或二烷基氨基,式Ⅲ为:
式中Hal是Cl或Br,X和Y定义如前,式Ⅳ为:
通过在氢化催化剂存在下用氢处理该次膦酸酯使其氢解,形成式IA′化合物的外消旋混合物(非对映异构体混合物)对,式AI′为:
将非对映异构体混合物分离成下列外消旋对:
通过用拆分剂处理,拆分该外消旋混合物,形成式Ⅴ拆分后的盐
2、权利要求1所述方法,其中拆分剂是L-辛可尼定,R是芳烷基,R是氢,n是0,X是低级烷基,y是低级烷基。
4、权利要求1所述方法,其中囟代酯是:
有机碱是三乙胺,并且该反应在甲苯中进行。
6、权利要求1所述方法,其中将非对映异构体混合物重结晶,借以分离出外消旋混合物对。
9、权利要求8所述的方法,其中所说醇是苄醇,或者所说氯甲酸芳烷基酯是氯甲酸苄基酯。
10、权利要求8所述方法,其中所说醇是苄醇,该酯化反应在甲苯和催化量的对甲基苯磺酸存在下进行,或者其中所说氯甲酸芳烷基酯是氯甲酸苄基酯,该酯化反应是在三乙胺存在下进行。
12、权利要求11所述方法,其中偶合剂是N,N-二环己基碳化亚胺,羰基二咪唑,巯基苯并三唑或新戊酰氯,所说活化剂是羟基苯并三唑,碱是二异丙基乙胺或三乙胺。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US102,694 | 1987-09-30 | ||
US07/102,694 US4873356A (en) | 1987-09-30 | 1987-09-30 | Method for preparing phosphinic acids used in preparing ace inhibitors and intermediates produced thereby |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1032443A true CN1032443A (zh) | 1989-04-19 |
Family
ID=22291193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN88109034A Pending CN1032443A (zh) | 1987-09-30 | 1988-09-29 | 用于制备ace抑制剂的次膦酸和中间体的制备方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US4873356A (zh) |
JP (1) | JP2716746B2 (zh) |
KR (1) | KR890005133A (zh) |
CN (1) | CN1032443A (zh) |
CA (1) | CA1336433C (zh) |
DE (1) | DE3833082A1 (zh) |
FI (1) | FI884200A (zh) |
FR (1) | FR2623811B1 (zh) |
GB (1) | GB2210370B (zh) |
HU (1) | HU205126B (zh) |
IE (1) | IE61587B1 (zh) |
IT (1) | IT1226859B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008399A (en) * | 1990-01-19 | 1991-04-16 | E. R. Squibb & Sons, Inc. | Diastereoselective preparation of phosphinate esters |
US6384022B1 (en) * | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
DE60106497D1 (de) * | 2001-04-30 | 2004-11-18 | Lupin Lab Ltd | Ein verfahren zur herstellung von natrium fosinopril |
KR100690647B1 (ko) | 2004-07-29 | 2007-03-09 | 엘지전자 주식회사 | 바스켓 승강장치를 구비한 냉장고 |
CN100497335C (zh) * | 2005-10-27 | 2009-06-10 | 上海医药工业研究院 | 取代氧膦基乙酸的光学拆分方法 |
CN100488969C (zh) * | 2005-10-27 | 2009-05-20 | 上海医药工业研究院 | 光学活性的取代氧膦基乙酸盐及其用途 |
IT1394407B1 (it) * | 2009-05-25 | 2012-06-15 | Dipharma Francis Srl | Procedimento per la preparazione di fosinopril e suoi intermedi |
IT1406151B1 (it) | 2010-12-06 | 2014-02-14 | Dipharma Francis Srl | Procedimento per la preparazione di fosinopril e suoi intermedi |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4396772A (en) * | 1981-11-23 | 1983-08-02 | F. R. Squibb & Sons, Inc. | Phosphinylalkanoyl amino acids |
US4448772A (en) * | 1982-04-22 | 1984-05-15 | E. R. Squibb & Sons, Inc. | Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension |
US4468519A (en) * | 1982-06-14 | 1984-08-28 | E. R. Squibb & Sons, Inc. | Esters of phosphinylalkanoyl substituted prolines |
US4602092A (en) * | 1983-09-19 | 1986-07-22 | E. R. Squibb & Sons, Inc. | Method for making phosphinic acid intermediates |
-
1987
- 1987-09-30 US US07/102,694 patent/US4873356A/en not_active Expired - Lifetime
-
1988
- 1988-08-31 CA CA000576217A patent/CA1336433C/en not_active Expired - Fee Related
- 1988-09-13 FI FI884200A patent/FI884200A/fi not_active Application Discontinuation
- 1988-09-27 GB GB8822596A patent/GB2210370B/en not_active Expired - Lifetime
- 1988-09-29 CN CN88109034A patent/CN1032443A/zh active Pending
- 1988-09-29 KR KR1019880012595A patent/KR890005133A/ko not_active Application Discontinuation
- 1988-09-29 HU HU885069A patent/HU205126B/hu unknown
- 1988-09-29 DE DE3833082A patent/DE3833082A1/de not_active Ceased
- 1988-09-29 FR FR888812769A patent/FR2623811B1/fr not_active Expired - Lifetime
- 1988-09-29 IT IT8822122A patent/IT1226859B/it active
- 1988-09-30 JP JP63248943A patent/JP2716746B2/ja not_active Expired - Lifetime
- 1988-10-29 IE IE293888A patent/IE61587B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IE61587B1 (en) | 1994-11-16 |
IT8822122A0 (it) | 1988-09-29 |
FI884200A (fi) | 1989-03-31 |
GB8822596D0 (en) | 1988-11-02 |
GB2210370B (en) | 1992-01-15 |
FR2623811A1 (fr) | 1989-06-02 |
FI884200A0 (fi) | 1988-09-13 |
US4873356A (en) | 1989-10-10 |
IT1226859B (it) | 1991-02-19 |
JP2716746B2 (ja) | 1998-02-18 |
HUT48632A (en) | 1989-06-28 |
GB2210370A (en) | 1989-06-07 |
CA1336433C (en) | 1995-07-25 |
JPH01106894A (ja) | 1989-04-24 |
DE3833082A1 (de) | 1989-04-13 |
HU205126B (en) | 1992-03-30 |
KR890005133A (ko) | 1989-05-13 |
IE882938L (en) | 1989-03-30 |
FR2623811B1 (fr) | 1991-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1106396A (zh) | 用于制备具有抗糖尿病和抗肥胖症性能的芳香氨基醇衍生物的中间化合物 | |
CN1172481A (zh) | 1-(巯甲基)环丙烷乙酸的制备工艺 | |
FR2596393A1 (fr) | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant | |
CN1132203A (zh) | 由N-保护的氨基酸酯制备N-保护的氨基酸α-卤代甲基酮和醇的方法 | |
CN1032443A (zh) | 用于制备ace抑制剂的次膦酸和中间体的制备方法 | |
CN1266148C (zh) | 制备2-吖丁啶酮衍生物的方法 | |
CN1860115A (zh) | 制备手性丙酸衍生物的方法 | |
Kalashnikov et al. | Facile method for the synthesis of oseltamivir phosphate | |
CN1026791C (zh) | 膦酸酯的非对映选择制备 | |
CN85101426A (zh) | 旋光的二-〔3-氯-2-氧-丙基三甲基铵〕-酒石酸盐的制备方法 | |
CN1025194C (zh) | 2-氮杂双环(2,2,1)庚-5-烯-2-乙酸衍生物和相关化合物的制备方法 | |
EP0000035A1 (en) | Alpha-amino acids, compositions and process for preparing said compounds | |
CN1100143A (zh) | 酶催化拆分2-哌啶羟酸烷基酯及所得产物的应用 | |
CN1269795A (zh) | 制备烷氧基呋喃酮胺衍生物的方法、通过该方法得到的化合物和这些化合物的用途 | |
CN1120840C (zh) | 拉米呋定的制备方法 | |
JP2004520440A (ja) | フォシノプリルナトリウムの製造方法 | |
KR100341256B1 (ko) | 리파제를 이용한 베라파밀 중간체의 분할 및 (r)- 및 (s)-베라파밀의 제조 방법 | |
EP0434743A1 (en) | Methods for preparing captopril and its analogues | |
US5237073A (en) | Derivatives and precursors of captopril and its analogues | |
EP0432204A4 (en) | Derivatives and precursors of captopril and its analogues | |
CN1070647A (zh) | 制备具有光学活性的假蟾毒胺醇的方法 | |
WO2006059347A2 (en) | Improved process for preparation of ramipril | |
JPH0832677B2 (ja) | (トランス)−4−フェニル−l−プロリン誘導体の製造法 | |
CN1618795A (zh) | 制备1,3-氧硫杂戊烷类核苷的立体异构体的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |